HUTCHMED (China) (HMDCF) Liabilities and Shareholders Equity (2015 - 2025)
HUTCHMED (China) (HMDCF) reported Liabilities and Shareholders Equity of $225.4 million for Q4 2025, up 37.53% year-over-year from $163.9 million in Q4 2024, and down 87.31% quarter-over-quarter from $1.8 billion in Q2 2025.
HUTCHMED (China) (HMDCF) Liabilities and Shareholders Equity (2015 - 2025) Analysis & Trends
HUTCHMED (China) (HMDCF) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $225.4 million in Q4 2025.
- Liabilities and Shareholders Equity for Q4 2025 came in at $225.4 million, up 37.53% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.3 billion (up 373.98% YoY), and the FY2025 annual result was $225.4 million, up 37.53% from the prior year.
- Liabilities and Shareholders Equity fell to $225.4 million in Q4 2025 per HMDCF's latest filing, from $1.8 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q2 2025 and troughed at $163786.0 in Q4 2023.
- A 5-year average of $541.9 million and a median of $176.2 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity slumped 99.88% in 2023, then surged 99970.22% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $176.2 million in 2021, then fell by 25.32% to $131.6 million in 2022, then plunged by 99.88% to $163786.0 in 2023, then surged by 99970.22% to $163.9 million in 2024, then soared by 37.53% to $225.4 million in 2025.
- Business Quant data shows HMDCF's Liabilities and Shareholders Equity at $225.4 million in Q4 2025, $1.8 billion in Q2 2025, and $163.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 2.27 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 2.35 Bn |
| 10 | HUTCHMED (China) | - | - | - | 225.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 225.41 Mn |
| Jun 30, 2025 | 1.78 Bn |
| Dec 31, 2024 | 163.90 Mn |
| Jun 30, 2024 | 161.29 Mn |
| Dec 31, 2023 | 163,786.01 |
| Jun 30, 2023 | 165.50 Mn |
| Dec 31, 2022 | 131.60 Mn |
| Jun 30, 2022 | 1.19 Bn |
| Dec 31, 2021 | 176.22 Mn |
| Jun 30, 2021 | 1.27 Bn |
| Mar 31, 2021 | 693.12 Mn |
| Dec 31, 2020 | 624.10 Mn |
| Jun 30, 2020 | 525.56 Mn |
| Dec 31, 2019 | 412.12 Mn |
| Sep 30, 2019 | 454.09 Mn |
| Jun 30, 2019 | 495.21 Mn |
| Mar 31, 2019 | 539.30 Mn |
| Dec 31, 2018 | 532.12 Mn |
| Jun 30, 2018 | 577.94 Mn |
| Dec 31, 2017 | 597.93 Mn |